Endoscopic Assisted Calcium Electroporation in Esophageal Cancer
Study Details
Study Description
Brief Summary
In this pilot study, patients with non-curable esophageal cancer will be treated with endoscopic assisted calcium electroporation (CaEP). CaEP is a novel cancer treatment where intratumoral injection with calcium is combined with locally applied electrical pulses, in order to increase calcium influx which leads to tumor necrosis.
It is hypothesized that:
-
Endoscopic assisted CaEP is a safe and feasible procedure in patients with non-curable esophageal cancer
-
CaEP debulks the tumor, facilitating the patient's ability to eat and drink
In this single-arm pilot study, eight patients will be treated.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Electroporation facilitates the transport of molecules across the cell membrane and into the cell by means of electrical pulses. An electric field applied to the cell destabilizes the cell membrane forming cracks, which reseals after a few minutes. During this time slot, molecules which normally are impermeable to the cell membrane are able to cross into the cytosol of the cell. Within the last ten years, studies have shown that the combination of intratumoral injection of calcium and electroporation (Calcium electroporation/CaEP) is an effective method in killing cancer cells. CaEP has been evaluated in clinical studies in colorectal cancer, carcinomas in the head and neck area, and in cutaneous metastases with promising results.
In this single-arm pilot study, eight patients with non-curable esophageal cancer will be included.
It is hypothesized that:
-
Endoscopic assisted CaEP is a safe and feasible procedure in patients with non-curable esophageal cancer
-
CaEP debulks the tumor, facilitating the patient's ability to eat and drink
-
CaEP induces a systemic immunological response
The primary objective is to evaluate the safety of CaEP for esophageal cancer. Adverse Events (AE) and Serious Adverse Events (SAE) will be evaluated.
Secondary outcomes include:
-
dysphagia (Mellow Pinkas dysphagia score)
-
pain (Numeric Rating Scale, NRS)
-
quality of life (QoL) (EORTC QLQ-C30)
-
tumor response evaluated from computed tomography (CT) and upper endoscopy
-
immunologic response
Tertiary outcomes include:
✓ 90-days survival
Participants are initially treated once according to protocol. If well-tolerated, the treatment can be repeated.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Calcium electroporation Calcium gluconate 0.23 mmol/ml Maxium dosage 20 ml Intra tumoral injection |
Drug: Calcium Gluconate
Calcium electroporation
|
Outcome Measures
Primary Outcome Measures
- Safety [14 days after treatment]
Registration of all AE/SAE´s within the first 14 days after treatment. The events will be assessed by CTCAE v4.0.
Secondary Outcome Measures
- Dysphagia [After 7 days, 2-4 weeks and after 6-8 weeks.]
According to Mellow Pinkas dysphgia scale
- Pain [After 7 days, 2-4 weeks and after 6-8 weeks.]
Assesed by Numerical Rating Scale
- Qualitiy of life [After 7 days, 2-4 weeks and after 6-8 weeks.]
Assesed by "EORTC QLQ-C30"
- 90 days survival [90 days]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female ≥18 years old.
-
Histological verified malignant tumor in the esophagus.
-
Subjects must have been considered unsuitable for potential curative treatment.
-
Locally progressive disease, and other standard oncological treatment have been administrated and/or considered first.
-
Performance status ECOG/WHO < 2.
-
Expected survival > 3 months.
-
Platelets ≥ 50 billion/l, International Normalized Ratio (INR) < 1,5.
-
Subjects must be willing and able to comply with the procedure such as agreed follow-up visits.
-
Women of childbearing potential (WOCBP) and male partners to WOCBP should use adequate contraception during the trial.
-
Subjects must give written informed consent.
Exclusion Criteria:
-
Coagulation disorder that cannot be corrected.
-
Subjects with a clinically significant cardiac arrhythmia.
-
Pregnancy or lactation.
-
Concurrent treatment with another investigational medicinal product.
-
Stenosis that prevents passage of the endoscope with the device attached.
-
Patients with any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study requirements.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Rigshospitalet | Copenhagen | Denmark | 2100 |
Sponsors and Collaborators
- Michael Patrick Achiam
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- eCaEP2021